Online First

June 25, 2020

Correspondence response
Response to: ‘COVID-19 in patients with rheumatological diseases treated with Anti-TNF’ by Brito et al and ‘Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences’ by Zhao et al
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace

doi: 10.1136/annrheumdis-2020-218196
Correspondence response
Is a human in vitro enthesitis model relevant to SpA-associated enthesitis? Response to: ‘Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease’ by Alunno et al
Free

Abdulla Watad, Hannah Rowe, Darren Newton, Charlie Bridgewood, Dennis G McGonagle

doi: 10.1136/annrheumdis-2020-218151
Correspondence
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors
Free

Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, María-del-Carmen López-González, Pilar Bernabeu, Agustín Martínez, Joaquim Esteve-Vives, Jose-Manuel León-Ramírez, Oscar Moreno-Perez, Vicente Boix, Joan Gil, Esperanza Merino, Paloma Vela, Mariano Andrés

doi: 10.1136/annrheumdis-2020-218152
Correspondence
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
Free

Zoé Gendebien, Christian von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, Laurence Seidel, Michel G Malaise, Olivier Malaise

doi: 10.1136/annrheumdis-2020-218244
Correspondence response
Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace

doi: 10.1136/annrheumdis-2020-218179
Correspondence
Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic
Free

Pedro Santos-Moreno, Josefina Chavez-Chavez, Sandra Milena Hernández-Zambrano, Diana Patricia Rivera-Triana, Ruth Alexandra Castiblanco-Montañez, Anggie Aza, Diana Buitrago-Garcia, Laura Villarreal, Adriana Rojas-Villarraga

doi: 10.1136/annrheumdis-2020-218165
Correspondence response
Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al
Free

Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna

doi: 10.1136/annrheumdis-2020-218193

June 24, 2020

Letter
Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19
Free

Panayiotis G Vlachoyiannopoulos, Eleni Magira, Haris Alexopoulos, Edison Jahaj, Katerina Theophilopoulou, Anastasia Kotanidou, Athanasios G Tzioufas

doi: 10.1136/annrheumdis-2020-218009
Correspondence
Comment on: ‘Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis’ by Kuwabara et al
Free

Valeria Rios Rodriguez, Judith Rademacher, Mikhail Protopopov, Murat Torgutalp, Hildrun Haibel, Janis Lucas Vahldiek, Ann-Christin von Brünneck, Safwan Omran, Denis Poddubnyy, Fabian Proft

doi: 10.1136/annrheumdis-2020-217894
Vasculitis
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Rona M Smith, Rachel Bronwen Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Aljayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Ahmed Luqmani, Hirofumi Makino, Carole McAlear, Paul Monach, Larry W Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Fiona Pearce, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L Rhee, Robert Spiera, Antoine G Sreih, Vladimir Tesar, Giles Walters, Michael H Weisman, Caroline Wroe, Peter Merkel, David Jayne RITAZAREM coinvestigators

doi: 10.1136/annrheumdis-2019-216863
Spondyloarthritis
Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

Raphael Micheroli, Christoph Tellenbach, Almut Scherer, Kristina Bürki, Karin Niederman, Michael J Nissen, Pascal Zufferey, Pascale Exer, Burkhard Möller, Diego Kyburz, Adrian Ciurea

doi: 10.1136/annrheumdis-2019-215934
Correspondence response
Response to: ‘Comment on: ‘Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis’ by Kuwabara et al’ by Rios Rodriguez et al
Free

Shun Tanimura, Hiroyuki Nakamura, Tetsuya Horita

doi: 10.1136/annrheumdis-2020-218055
Correspondence response
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al
Free

Hendrik Schulze-Koops, Christof Specker, Klaus Krueger

doi: 10.1136/annrheumdis-2020-218235
Correspondence
Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak
Free

Ho So, Cheuk-Chun Szeto, Lai-Shan Tam

doi: 10.1136/annrheumdis-2020-218220

June 23, 2020

Correspondence response
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic et al
Free

Hendrik Schulze-Koops, Klaus Krueger, Christof Specker On behalf of the Kommission Pharmakotherapie of the German Society of Rheumatology

doi: 10.1136/annrheumdis-2020-218223
Correspondence
Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience
Free

Rita Angélica Pineda-Sic, Dionicio Angel Galarza-Delgado, Griselda Serna-Peña, Sergio A Castillo-Torres, Diana Elsa Flores-Alvarado, Jorge A Esquivel-Valerio, Iván De Jesús Hernández-Galarza

doi: 10.1136/annrheumdis-2020-218198

June 22, 2020

Autoinflammatory disorders
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Seza Ozen, Eldad Ben-Cherit, Ivan Foeldvari, Gil Amarilyo, Huri Ozdogan, Steven Vanderschueren, Katherine Marzan, J Michelle Kahlenberg, Elise Dekker, Fabrizio De Benedetti, Isabelle Koné-Paut

doi: 10.1136/annrheumdis-2020-217419
Correspondence response
Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
Free

Carmen Magdalena Gamboa-Alonso, Gabriel Figueroa-Parra, Dionicio Angel Galarza-Delgado

doi: 10.1136/annrheumdis-2020-217633
Epidemiology
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’
Free

Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Xiaoqing Fu, Ellen M Gravallese, Hyon K Choi, Jeffrey A Sparks, Zachary S Wallace

doi: 10.1136/annrheumdis-2020-217888
Correspondence
Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues
Free

Hadis Ghajari, Siamak Sabour

doi: 10.1136/annrheumdis-2020-218038
Correspondence response
Response to: ‘Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues’ by Ghajari and Sabour
Free

Kornelis SM van der Geest, Frances Borg, Abdul Kayani, Davy Paap, Prisca Gondo, Wolfgang Schmidt, Raashid Ahmed Luqmani, Bhaskar Dasgupta

doi: 10.1136/annrheumdis-2020-218144

June 19, 2020

Systemic sclerosis
Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients

Lorenzo Beretta, Guillermo Barturen, Barbara Vigone, Chiara Bellocchi, Nicolas Hunzelmann, Ellen De Langhe, Ricard Cervera, Maria Gerosa, László Kovács, Rafaela Ortega Castro, Isabel Almeida, Divi Cornec, Carlo Chizzolini, Jacques-Olivier Pers, Zuzanna Makowska, Ralf Lesche, Martin Kerick, Marta Eugenia Alarcón-Riquelme, Javier Martin, PRECISESADS SSc substudy group PRECISESADS Flow Cytometry study group

doi: 10.1136/annrheumdis-2020-217116
Correspondence response
Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al
Free

Vasco C Romão, Ana Rita Cruz-Machado, João Eurico Fonseca

doi: 10.1136/annrheumdis-2020-218175
Correspondence
Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients
Free

Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali

doi: 10.1136/annrheumdis-2020-218068
Correspondence response
Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: ‘Online management of rheumatoid arthritis during COVID-19 pandemic’ by Zhang et al
Free

Gabriel Figueroa-Parra, Carmen Magdalena Gamboa-Alonso, Dionicio Angel Galarza-Delgado

doi: 10.1136/annrheumdis-2020-217631
Correspondence response
Hypersensitivity reactions with allopurinol versus febuxostat in the US elderly. Response to: ‘Confunding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’’ by Hsu et al
Free

Jasvinder A Singh

doi: 10.1136/annrheumdis-2020-218150
Correspondence
Understanding bone fragility: theoretical explanation to non-physician health professionals
Free

Toshihiro Sugiyama

doi: 10.1136/annrheumdis-2020-218003
Correspondence response
Response to: ‘Understanding bone fragility: theoretical explanation to non-physician health professionals’ by Sugiyama
Free

Jo Adams, Nicky Wilson, Tanja A Stamm

doi: 10.1136/annrheumdis-2020-218049
Correspondence
Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Free

Kevin Sheng-Kai Ma, James Cheng-Chung Wei, Wen-Hung Chung

doi: 10.1136/annrheumdis-2020-218090
Correspondence
Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Free

Po-Ke Hsu, Yung-Heng Lee, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2020-218056
Correspondence response
Allopurinol versus febuxostat hypersensitivity reactions in the US elderly: differences in study outcomes and populations. Response to: ‘Correspondence to “Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’ by Ma et al
Free

Jasvinder A Singh

doi: 10.1136/annrheumdis-2020-218149

June 18, 2020

Editorial
Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?
Free

Gabriel Herrero-Beaumont, Raquel Largo

doi: 10.1136/annrheumdis-2020-217454

June 16, 2020

Autoinflammatory disorders
Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study
Free

Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, Ying Huang, Hui Wang, Pan Shen, Xin Ba, Weiji Lin, Hui Dong, Mingmin Zhang, Shenghao Tu

doi: 10.1136/annrheumdis-2020-217425
Letter
Standardisation of PR3-ANCA and MPO-ANCA: evaluation of certified reference materials

Xavier Bossuyt, Doreen Dillaerts, Michael Mahler, Dirk Roggenbuch, Ulrich Leinfelder, Friederike Hammar, Wolfgang Schlumberger, Nina Olschowka, Jan Damoiseaux

doi: 10.1136/annrheumdis-2020-217416
Correspondence
COVID-19 in patients with rheumatological diseases treated with anti-TNF
Free

Carlos Antunes Brito, José Gerardo Paiva, Fernando Nunes Pimentel, Rosinete Santos Guimarães, Mariana Ribeiro Moreira

doi: 10.1136/annrheumdis-2020-218171
Myositis
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis

Iago Pinal-Fernandez, Maria Casal-Dominguez, Assia Derfoul, Katherine Pak, Frederick W Miller, Jose César Milisenda, Josep Maria Grau-Junyent, Albert Selva-O'Callaghan, Carme Carrion-Ribas, Julie J Paik, Jemima Albayda, Lisa Christopher-Stine, Thomas E Lloyd, Andrea M Corse, Andrew L Mammen

doi: 10.1136/annrheumdis-2019-216599

June 12, 2020

Correspondence
Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications
Free

Vincenzo L'Imperio, Gisella Vischini, Fabio Pagni, Pietro Manuel Ferraro

doi: 10.1136/annrheumdis-2020-217979
Correspondence
Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease
Free

Alessia Alunno, Onelia Bistoni, Roberto Gerli

doi: 10.1136/annrheumdis-2020-218094
Correspondence response
Selection of appropriate outcome measure in ANCA-associated vasculitis. Response to: ‘Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’ by L'Imperio et al
Free

Dilek Solmaz, Servet Akar

doi: 10.1136/annrheumdis-2020-218035

June 11, 2020

Correspondence
Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
Free

Luisa Costa, Marco Tasso, Nadia Scotti, Erika Mostacciuolo, Nicolò Girolimetto, Francesca Foglia, Antonio del Puente, Raffaele Scarpa, Francesco Caso

doi: 10.1136/annrheumdis-2020-217806
Viewpoint
Digital crowdsourcing: unleashing its power in rheumatology
Free

Martin Krusche, Gerd R Burmester, Johannes Knitza

doi: 10.1136/annrheumdis-2020-217697
Correspondence response
Response to: ‘Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome’ by Xie et al
Free

Yueting Li, Yihan Cao, Chen Li, Wen Zhang

doi: 10.1136/annrheumdis-2020-217956
Correspondence
Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome
Free

Wenhui Xie, Hong Huang, Zhuoli Zhang

doi: 10.1136/annrheumdis-2020-217854

June 10, 2020

Letter
Biologics, spondylitis and COVID-19
Free

James Todd Rosenbaum, Hedley Hamilton, Dongseok Choi, Michael H Weisman, John D Reveille, Kevin L Winthrop

doi: 10.1136/annrheumdis-2020-217941

June 08, 2020

Correspondence response
Response to: ‘Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak’ by Holubar et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-217988
Correspondence
Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak
Free

Jan Holubar, Moglie Le Quintrec, Hind Letaief, Jean Luc Faillie, Yves-Marie Pers, Christian Jorgensen

doi: 10.1136/annrheumdis-2020-217919
Correspondence
Pisotriquetral arthritis: ‘forgotten’ joint in ultrasound imaging of the wrist
Free

Andrea Becciolini, Alarico Ariani, Marco Becciolini

doi: 10.1136/annrheumdis-2020-217980
Correspondence response
Which joints and what pathological findings should be evaluated on ultrasound in CCP+ at-risk individuals? The fifth MTP joint for bone erosions is a good starting point. Response to: ‘Pisotriquetral arthritis: ‘forgotten’ joint in ultrasound imaging of the wrist’ by Becciolini et al
Free

Andrea Di Matteo, Kulveer Mankia, Richard J Wakefield, Paul Emery

doi: 10.1136/annrheumdis-2020-218036

June 05, 2020

Correspondence
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Free

Jérôme Avouac, Paolo Airó, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore

doi: 10.1136/annrheumdis-2020-217864
Correspondence response
Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al
Free

Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

doi: 10.1136/annrheumdis-2020-217955

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

June 25, 2020

June 24, 2020

June 23, 2020

June 22, 2020

June 19, 2020

June 18, 2020

June 16, 2020

June 12, 2020

June 11, 2020

June 10, 2020

June 08, 2020

June 05, 2020

Pages